Evaluating the effect of a Russian rituximab biosimilar used to treat patients with rheumatoid arthritis on healthcare budgets
Objective: to evaluate the economic impact of therapy with a Russian rituximab (RTM) biosimilar (Acellbia®) in patients with rheumatoid arthritis (RA) on the healthcare budget of the Russian Federation.Material and methods. A review of literature data and economic modeling (budget impact analysis) w...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2018-06-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/826 |
| _version_ | 1797876727814291456 |
|---|---|
| author | R. O. Dreval |
| author_facet | R. O. Dreval |
| author_sort | R. O. Dreval |
| collection | DOAJ |
| description | Objective: to evaluate the economic impact of therapy with a Russian rituximab (RTM) biosimilar (Acellbia®) in patients with rheumatoid arthritis (RA) on the healthcare budget of the Russian Federation.Material and methods. A review of literature data and economic modeling (budget impact analysis) were carried out.Results. The use of the RTM biosimilar Acellbia® to treat patients with RA is appropriately and economically justified through drug supply within any funding source: a compulsory health insurance (CHI) system (for high-tech medical care or a diagnosis-related group); an essential medicines provision program, and a regional subsidized drug list.Conclusion. The budget burden over the next three years, the budget burden will be reduced from 6% will be reduced from 6% in the CHI system to 13% in the regional subsidized drug list, which will bring additional more than 1.5 billion rubles. A further reduction in the price of a RTM biosimilar as a result of competitive activity and the potential emergence of other biosimilars will lead to a further rise in budget saving. |
| first_indexed | 2024-04-10T02:06:03Z |
| format | Article |
| id | doaj.art-1c37f047d93c4e398381c52705739718 |
| institution | Directory Open Access Journal |
| issn | 1996-7012 2310-158X |
| language | Russian |
| last_indexed | 2024-04-10T02:06:03Z |
| publishDate | 2018-06-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj.art-1c37f047d93c4e398381c527057397182023-03-13T08:39:26ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2018-06-01122586310.14412/1996-7012-2018-2-58-632093Evaluating the effect of a Russian rituximab biosimilar used to treat patients with rheumatoid arthritis on healthcare budgetsR. O. Dreval0НП «Центр Социальной Экономики»Objective: to evaluate the economic impact of therapy with a Russian rituximab (RTM) biosimilar (Acellbia®) in patients with rheumatoid arthritis (RA) on the healthcare budget of the Russian Federation.Material and methods. A review of literature data and economic modeling (budget impact analysis) were carried out.Results. The use of the RTM biosimilar Acellbia® to treat patients with RA is appropriately and economically justified through drug supply within any funding source: a compulsory health insurance (CHI) system (for high-tech medical care or a diagnosis-related group); an essential medicines provision program, and a regional subsidized drug list.Conclusion. The budget burden over the next three years, the budget burden will be reduced from 6% will be reduced from 6% in the CHI system to 13% in the regional subsidized drug list, which will bring additional more than 1.5 billion rubles. A further reduction in the price of a RTM biosimilar as a result of competitive activity and the potential emergence of other biosimilars will lead to a further rise in budget saving.https://mrj.ima-press.net/mrj/article/view/826анализ влияния на бюджетревматоидный артритритуксимаббиоаналоггенно-инженерные биологические препараты |
| spellingShingle | R. O. Dreval Evaluating the effect of a Russian rituximab biosimilar used to treat patients with rheumatoid arthritis on healthcare budgets Современная ревматология анализ влияния на бюджет ревматоидный артрит ритуксимаб биоаналог генно-инженерные биологические препараты |
| title | Evaluating the effect of a Russian rituximab biosimilar used to treat patients with rheumatoid arthritis on healthcare budgets |
| title_full | Evaluating the effect of a Russian rituximab biosimilar used to treat patients with rheumatoid arthritis on healthcare budgets |
| title_fullStr | Evaluating the effect of a Russian rituximab biosimilar used to treat patients with rheumatoid arthritis on healthcare budgets |
| title_full_unstemmed | Evaluating the effect of a Russian rituximab biosimilar used to treat patients with rheumatoid arthritis on healthcare budgets |
| title_short | Evaluating the effect of a Russian rituximab biosimilar used to treat patients with rheumatoid arthritis on healthcare budgets |
| title_sort | evaluating the effect of a russian rituximab biosimilar used to treat patients with rheumatoid arthritis on healthcare budgets |
| topic | анализ влияния на бюджет ревматоидный артрит ритуксимаб биоаналог генно-инженерные биологические препараты |
| url | https://mrj.ima-press.net/mrj/article/view/826 |
| work_keys_str_mv | AT rodreval evaluatingtheeffectofarussianrituximabbiosimilarusedtotreatpatientswithrheumatoidarthritisonhealthcarebudgets |